Cost‐Effectiveness of LDL ‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States-Reference-Cited by-同舟云学术

Cost‐Effectiveness of LDL ‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

Author:

Gandra Shravanthi R.¹,Villa Guillermo²,Fonarow Gregg C.³,Lothgren Mickael²,Lindgren Peter⁴⁵,Somaratne Ransi⁶,van Hout Ben⁷

Affiliation:

1. Department of Global Health Economics, Amgen Inc. Thousand Oaks, California

2. Economic Modeling Center, Amgen (Europe) GmbH, Zug Switzerland

3. Ahmanson‐UCLA Cardiomyopathy Center, Division of Cardiology Geffen–UCLA School of Medicine Los Angeles, California

4. Department of Health Economics the Swedish Institute for Health Economics Lund Sweden

5. Department of Learning, Informatics, Management and Ethics Karolinska Institute Stockholm Sweden

6. Department of Clinical Development, Amgen Inc. Thousand Oaks, California

7. Department of Health Economics University of Sheffield Sheffield United Kingdom

Publisher

Wiley

Subject

Cardiology and Cardiovascular Medicine,General Medicine

Link

Reference40 articles.

1. Heart disease and stroke statistics—2015 update: a report from the American Heart Association;Mozaffarian D;Circulation.,2015

Cited by 76 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献